29,977 Alto Neuroscience, Inc. $ANRO Shares Bought by Profund Advisors LLC

Posted by George Bondi on Nov 4th, 2026

Profund Advisors LLC raised its stake in Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 379.1% in the third quarter, HoldingsChannel.com reports. The fund owned 37,885 shares of the company’s stock after purchasing an additional 29,977 shares during the quarter. Profund Advisors LLC’s holdings in Alto Neuroscience were worth $967,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in ANRO. Commodore Capital LP lifted its position in shares of Alto Neuroscience by 49.4% in the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after acquiring an additional 900,000 shares in the last quarter. Perceptive Advisors LLC increased its position in Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Spruce Street Capital LP increased its position in Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after purchasing an additional 1,102,366 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in Alto Neuroscience during the 1st quarter worth about $11,240,000. Finally, Jennison Associates LLC acquired a new position in Alto Neuroscience in the 1st quarter valued at about $8,687,000.

Analyst Ratings Changes

ANRO has been the topic of a number of recent research reports. HC Wainwright upped their target price on shares of Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Monday, October 19th. BTIG Research lifted their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Finally, Wedbush lifted their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.88.

Get Our Latest Report on ANRO

Alto Neuroscience Stock Performance

NYSE ANRO opened at $22.72 on Wednesday. Alto Neuroscience, Inc. has a 12 month low of $10.20 and a 12 month high of $37.48. The company has a 50-day moving average of $27.77 and a 200-day moving average of $24.22. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, analysts anticipate that Alto Neuroscience, Inc. will post -2.69 earnings per share for the current year.

Insider Buying and Selling at Alto Neuroscience

In other Alto Neuroscience news, CFO Nicholas Smith sold 110,830 shares of Alto Neuroscience stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $26.58, for a total value of $2,945,861.40. Following the transaction, the chief financial officer owned 24,060 shares in the company, valued at $639,514.80. This trade represents a 82.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.25% of the stock is currently owned by company insiders.

Alto Neuroscience Profile

(Free Report)

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments.

Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment.